Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00755352 · ClinicalTrials.gov registry record · Phase 4
A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.
A Phase 4 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 4
- Development phase
- 67
- Enrollment target
NCT00755352 is a Phase 4 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 67 participants.
The verdict
NCT00755352, a Phase 4 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 67 participants
- Enrollment target
Study Summary
Determine the effect of WelChol tablets on serum lipids, lipoproteins, apolipoproteins, and lipoprotein particle size in patients who were stabilized on pravastatin therapy for at least 4 weeks.
Interventions
- DRUG pravastatin tablets and Welchol tablets
- DRUG pravastatin tablets and Welchol placebo tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2002-11 |
| Est. Completion | 2005-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00755352
The ClinicalTrials.gov registry entry for NCT00755352 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pravastatin tablets and Welchol tablets is the first listed.
NCT00755352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00755352 about?
NCT00755352 is a clinical study titled "A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.". Determine the effect of WelChol tablets on serum lipids, lipoproteins, apolipoproteins, and lipoprotein particle size in patients who were stabilized on pravastatin therapy for at least 4 weeks.
What is the current status of trial NCT00755352?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 67 participants. The study started on 2002-11. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00755352?
The interventions under investigation include: pravastatin tablets and Welchol tablets (DRUG), pravastatin tablets and Welchol placebo tablets (DRUG).
Who is sponsoring clinical trial NCT00755352?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.